Previous studies have shown that the consumption and/or status in lipid micronutrients (fat-soluble vitamins, carotenoids, phytosterols, PUFAs, and some polyphenols) is associated with a reduced incidence of chronic and degenerative pathologies, including cardiometabolic diseases. Mechanisms involved are partly unveiled. They include both gene regulation and control of the redox/inflammatory state, but have yet to be explored in detail.
In addition, the bioavailability of lipid micronutrients is negatively influenced by many dietary and environmental factors, and varies considerably between individuals. Strategies to promote the absorption of lipid micronutrients should thus be developed.
We also study postprandial lipid metabolism, particularly chylomicrons (intestinal lipoproteins carrying both lipids and lipid micronutrients). Indeed, postprandial hyperlipidemia is recognized as a strong and independent predictor of atherosclerotic cardiovascular disease and all-cause mortality.
Our objectives are achieved through integrative biology approaches using complementary models, ranging from in vitro digestion models to clinical studies, and including cell culture, animal models and the use of cutting-edge analytical techniques such as metabolomics.

1. Understand the cellular and molecular basis of the mechanisms involved in immunothrombosis and vascular repair, with a specific focus on interactions between endothelium, polynuclear cells, endothelial progenitors, NETS and extracellular vesicles.
2. Identify new cellular and molecular targets and define innovative biomarkers, imaging strategies and biotherapies, enabling a personalized approach to vascular medicine to improve early prevention, diagnosis and treatment of cardiovascular disease.

1. characterize the structure/function of these proteins in different cell types, mainly endothelial cells
2. validate these proteins as therapeutic targets in diseases where endothelial dysfunction plays a role using preclinical cellular and mouse models.
3.  generate and clinically validate innovative diagnostic tests and produce new therapeutic approaches targeting AhR and CD146 for precision vascular medicine.

Our objectives:

• To propose new biomarkers, belonging to the adenosinergic system, for screening and monitoring of the cardiovascular diseases.
• To understand cardiovascular adaptation to extreme conditions.
• To identify innovative early biomarkers of cardiotoxicities induced by anti-cancer therapies.
• To characterize the pathophysiological mechanisms of heart disease.

Our team specializes in CRDs and is particularly interested in deciphering the function of this epithelium to better anticipate, treat and cure these complex diseases.
Through our studies, we aim to develop original biological markers and identify new therapeutic targets with the hope of interfering with the evolutionary engineering of these diseases. To achieve this, our projects are based on an original in vitro model of reconstitution of fully differentiated pseudostratified bronchial epithelium at the air-liquid interface, obtained directly from patient samples and maintaining its original characteristics.
Our current avenues of research envisage:
- The prevention and resolution of epithelium-orchestrated bronchial inflammation, particularly in the context of viral-induced exacerbations,
- Understanding the communication networks between the epithelium and inflammatory and/or structural cells,
- Mechanistic understanding and reprogramming of diseased bronchial epithelium,
- The development of innovative treatments through translational research based on national and international cohorts and networks.